CD274 and non-small cell lung carcinoma: Combined with chemotherapy, cadonilimab elicited an ORR of 65.9% in phase I/II trial for GC/GEJC.388 In the phase I/II trial for PD-L1 TPS ≥ 1% NSCLC, cadonilimab combined with anlotinib induced an ORR of 62.5%.389 Thus, cadonilimab combined with chemotherapy or targeted therapy elicited excellent ORRs (Table 2).